AYM Syntex Q1 FY27 Results (NSE: AYMSYNTEX)
Signal: Margin expansion
The read
The operating inflection is real but still early: revenue grew 7.5% YoY after three consecutive quarters of YoY declines, EBITDA margin expanded 420bps to 9.3% after three quarters of contraction, and EBITDA grew 74.2% versus revenue growth of 7.5%; however, PAT was overstated by the ₹227.50 lakh one-time deferred-tax credit and revenue declined 4.0% QoQ.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹351.02 Cr | 7.5% | -4.0% |
| EBIT | ₹17.77 Cr | 779.7% | |
| Net profit | ₹8.67 Cr | N/A | |
| EPS | ₹1.48 | 142.6% | |
| EBIT margin | 9.3% |
P&L walk
Revenue increased 7.5% YoY but declined 4.0% QoQ; gross margin improved 120bps YoY, while lower other expenses helped EBITDA margin reach 9.3%, and PAT turned positive at ₹866 lakh despite a ₹227.50 lakh deferred-tax credit.
Segments
The company reports only one segment, Synthetic Yarn; consolidated PAT of ₹866 lakh was effectively the standalone PAT of ₹867 lakh because the wholly owned subsidiary contributed a ₹0.06 lakh loss.
Key positives
- Revenue rose 7.5% YoY to ₹35,103 lakh, reversing the -14.3% YoY decline reported in Q3FY26.
- EBITDA increased 74.2% YoY to ₹3,268 lakh, versus revenue growth of 7.5%, and EBITDA margin expanded 420bps to 9.3%.
- Other expenses declined 3.3% YoY to ₹9,887 lakh while revenue grew 7.5%, supporting the margin recovery.
- Gross margin improved 120bps YoY to 44.7%, with raw-material cost including inventory movement declining to 55.3% of revenue from 56.5%.
Key concerns
- Revenue declined 4.0% QoQ to ₹35,103 lakh, so the recovery has not yet established sequential growth.
- The ₹866 lakh consolidated PAT includes a ₹227.50 lakh one-time deferred-tax credit; excluding this benefit, reported profit would be materially lower.
- Employee benefit expense rose 13.5% YoY to ₹2,661 lakh, faster than revenue growth of 7.5%, limiting the quality of fixed-cost absorption.
- Finance costs rose 8.0% YoY to ₹820 lakh despite the operating recovery.
Research and educational content only. Not investment advice.